Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome –Positive Chronic Myeloid Leukemia

The overall prognosis of Philadelphia chromosome –positive chronic myeloid leukemia patients is today considered to be good thanks to targeted therapy with tyrosin kinase inhibitors (TKIs). A study of a 86-patient cohort showed a strong association between imatinib intolerance and blastic phase development, opening the question if whether it is perhaps due to a more aggressive form of the disease intrinsically resistant to TKIs.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: SOHO Supplement 2016 Source Type: research